##### 



EXHIBIT 10.27
 *** Text Omitted and Filed Separatelywith the Securities and Exchange CommissionConfidential Treatment RequestUnder C.F.R. Sections 200.80(b)(4)and 240.24b-2




---



##### 








---



##### 



Agreement Execution Date Seller Buyer Section 9.1
    Product
  Exhibit A Transition Services
Agreement
  ARTICLE I
 ASSETS, LIABILITIES AND PURCHASE PRICE
 Purchase and Sale of Transferred Assets
 Transfer
 1.




---



##### 



Transferred Assets
 Product Regulatory Approvals Section 3.9(a)
 Promotional Materials
 Product Intellectual Property
 Section 1.8 Section
1.1(a)(iv) Assumed
Contracts
 provided however
 2.




---



##### 



Product Records
 Section
1.1(a)(vi) Inventory provided however Inventory Disposal Costs
 Section 1.1(a)(vii)
 Transfer of Other Intellectual Property
 Excluded Assets
 Excluded Assets Section 1.1
 ***Confidential Treatment Requested
 3.




---



##### 



Intellectual Property Section 5.18
 Assumed Liabilities Assumed Liabilities
  Section 2.4(a)
 Section 1.3(c) Amgen Materials
 Section 1.3(d) BI Materials Section 5.15(b)
 Section 1.3(e)
 Section 1.3 Section 1.3
 Excluded Liabilities
 Section 1.4(a)
 4.




---



##### 



Article VIII
 Article VIII
 Purchase Price Section 1.3 Purchase Price
 Closing
Payment
 Section 5.15(b)
 Section 5.15(a)
 Wholesaler Inventory Rebate
  Allocation of Purchase Consideration
 ***Confidential Treatment Requested
 5.




---



##### 



Section 1.7 Allocation
 Third Party Consents
   Further Conveyances and Assumptions
 6.




---



##### 



Risk of Loss
 ARTICLE II
 CLOSING, DELIVERIES, TAX MATTERS
 Closing Closing Article VI Closing Date Effective Time
 Deliveries by Seller
 Exhibit C Bill
of Sale
 Exhibit D General Assignment
 Exhibit
E Patent Assignment
 Exhibit F Trademark Assignment
 Exhibit G
  7.




---



##### 



Transition Related
Payments
  Deliveries by Buyer
         Certain Tax Matters
 Transfer Taxes and Costs
 8.




---



##### 



Transfer Taxes
 Pre-Closing Taxes Pre-Closing Period
 Post-Closing Taxes Post-Closing Period
 Straddle Period Taxes Straddle Period provided however Section 2.4(d)
 9.




---



##### 



Section
2.4(d) Section
2.4(d)
 Cooperation on Tax Matters
 Settlement of Tax Matters
 Tax Claims
 Tax Claim
 provided
 10.




---



##### 



Section 2.4(g)
 ARTICLE III
 REPRESENTATIONS AND WARRANTIES OF SELLER
  Corporate Existence
 Corporate Power and Authority Enforceability
Exceptions
 11.




---



##### 



Consents; No Violation
 Section 3.3(a) Regulatory Consents
 Section 3.3(b) Section 3.3(a)
 Tax Matters
    12.




---



##### 



No Product Material Adverse Effect Section 3.5
   Title to Transferred Assets
 Intellectual Property
  Section 3.7(b)
  13.




---



##### 



Section 3.7(h)
     14.




---



##### 



Compliance with Laws; Litigation
 Section 3.9 Section 3.8(a)
 Actions
   Regulatory Approvals
 Section 3.9(a)
  Section 3.9(c) Section 3.9(a)
 15.




---



##### 



Material Contracts
 Section 3.10 Material Contracts Section 3.10(a)
   Inventory Section 3.11
 Brokers Fees
   Sufficiency provided however
 ***Confidential Treatment Requested
 16.




---



##### 



Disclosure Letter Seller Disclosure Letter
 Financial Statements Product Financial Statements
 Product Records
 Insurance Claims
 No Other Representations and Warranties ARTICLE III
 ARTICLE IV
 REPRESENTATIONS AND WARRANTIES OF BUYER
  Corporate Existence
 ***Confidential Treatment Requested
 17.




---



##### 



Corporate Power and Authority
 Consents; No Violations
  Section 4.3(a)
 Financing
 Litigation
 ***Confidential Treatment Requested
 18.




---



##### 



Brokers Fees
   ARTICLE V
 COVENANTS
 Conduct of the Product Business
 Section
5.1
 Section 5.1(a)
 ***Confidential Treatment Requested
 19.




---



##### 



Access to Information provided however provided further Section 5.2
 Reasonable Best Efforts; Governmental Approvals; Material Consents
 ***Confidential Treatment Requested
 20.




---



##### 



Section 5.4
 Filings Under the HSR Act
 FTC DOJ
    Section 5.4
 21.




---



##### 



No Solicitation of Proposals Section
5.5
 Notice; Cure Article VI Section 5.1 Section
5.6 Article VIII
 Press Releases; Announcements
  22.




---



##### 



Financing
   Non Solicitation of Employees Section
5.13 provided that
 NDC Numbers, Product Returns, Rebates and Chargebacks
 NDC Numbers
 Product Returns
  ***Confidential Treatment Requested
 23.




---



##### 



Product Returns Section 5.10(b)(i)(A) Section 5.10(b)(i)(B) Section 5.1(b)(i)(B) Sections 5.10(b)(i)(A) (B)
 Returned Product
  Government Rebates
 Government Rebates
     ***Confidential Treatment Requested
 24.




---



##### 



Non-Responsible Party Responsible Party Section 5.10(c)(iii) Section 5.10(c)(ii) provided
 Section 5.10(c)(ii)
 Commercial Rebates
 Commercial
Rebates
  ***Confidential Treatment Requested
 25.




---



##### 



Section 5.10(d)(iii) Section 5.10(d)(ii) provided
 ***Confidential Treatment Requested
 26.




---



##### 



Section 5.10(d)(ii)
  Chargeback Claims
 Chargeback Claims
  ***Confidential Treatment Requested
 27.




---



##### 



Section
5.10(e)(iii) Section 5.10(d)(ii) provided
  Procedures
 Sections 5.10(c)(iii) 5.10(d)(iii) Section
5.10(e)(iii) provided however
 ***Confidential Treatment Requested
 28.




---



##### 



Section 9.3
 Customer Billing
   Covenant Not To Compete
 Employees
 ***Confidential Treatment Requested
 29.




---



##### 



Regulatory Matters
 Section 5.15
 Life Threatening SAE Non-Life Threatening SAE SAE
  ***Confidential Treatment Requested
 30.




---



##### 



provided however
 Transfer of Infergen Manufacturing Site
   Insurance Matters Section 3.13 Section 5.1
 ***Confidential Treatment Requested
 31.




---



##### 



Pricing Compliance Covenant.
 Section 5.17(b)
 Section 5.17(b) Sales Information
 Transitional Trademark License
 Seller Marks
 32.




---



##### 



Section 5.18 Section 5.18
 Section 5.18 Section 5.18
 Section 5.18 Section 5.18
 Section 5.18
  InterMune Agreement
 ***Confidential Treatment Requested
 33.




---



##### 



ARTICLE VI
 CONDITIONS TO CLOSING
 Conditions Precedent to Obligations of Buyer and Seller
 Injunction
 Authorizations Section 6.1(b)
 Conditions Precedent to Buyers Obligations
 Representations and Warranties Article III
 ***Confidential Treatment Requested
 34.




---



##### 



Performance of Obligations by Seller Section 2.2
 No Product Material Adverse Effect
 Material Consents
 Closing Certificate Sellers Closing Certificate
  Section 6.2(a) (b) (c)
 Financing
 Conditions Precedent to Sellers Obligations
 Representations and Warranties Article IV
 35.




---



##### 



Performance of Obligations by Buyer Section 2.3
 Closing Certificate Buyers Closing Certificate
  Section 6.3(a) (b)
 ARTICLE VII
 TERMINATION
 Termination Section
7.1(a)
  Outside Date provided however Section 7.1(b)
 provided however
 ***Confidential Treatment Requested
 36.




---



##### 



Section 7.1(c)
 Section
6.3(a) (b)
 Section
6.2(a) (b) (c)
 Effect of Termination
 Liability Section 7.1 provided however Section 7.1 Section 7.1 Section 5.2 Section 7.2 Article IX
 Fees and Expenses
 ARTICLE VIII
 INDEMNIFICATION
 Survival of Representations, Warranties and Agreements Sections 3.1 Corporate
Existence) 3.2 (Corporate Power and Authority) 3.6 (Title to Transferred Assets) 3.12 (Brokers Fees) Section 3.4 (Tax Matters) Sections 3.1 3.2 3.6 3.12 Excluded Representations
 ***Confidential Treatment Requested
 37.




---



##### 



provided Section
8.3
 Indemnification
 Sellers Indemnification Obligations Buyer Indemnitees Losses
 Article III
      Section 5.19
 Buyers Indemnification Obligations
 ***Confidential Treatment Requested
 38.




---



##### 



Seller Indemnitees
 Article IV
      Indemnification Procedures
 Third Party Claim Indemnified Party Indemnifying Party Indemnification Claim Notice
  39.




---



##### 



Section 8.3(c)
 Section 8.3(b) provided however Section 8.3(b)
 Section 8.3(b) provided however Section 8.3(b) provided Section 8.3(b) Section 8.3(b) provided however
  40.




---



##### 



Payment of Losses Article VIII Section 8.4 Electing Buyer
 Limitations
 Section 8.2(a)(i Basket Sections
8.2(a)(i 8.2(a)(ii) Section 8.2(a)(ii) Section 5.1(a) Section 5.1(b) only) Cap provided however
 Section 8.2(b)(i) Section 8.2(b)(i) provided however
 ***Confidential Treatment Requested
 41.




---



##### 



Sections 4.1 (Corporate Existence) 4.2 (Corporate
Power and Authority) 4.4 (Financing) 4.6 Brokers Fees
  Article III Article IV Article VIII
 Exclusive Remedy Article VIII provided however
 Calculation of Losses; Mitigation provided
 42.




---



##### 



Treatment of Indemnification Payments Article VIII
 ARTICLE IX
 MISCELLANEOUS PROVISIONS
 Definitions
  Affiliate
 Amgen
 Amgen Agreements
 Amgen Assignment, Assumption and Consent Agreement
 Amgen Consent
 Amgen Consent to Assignment Agreement
 Amgen License Agreement
 43.




---



##### 



Amgen License Rights
 Amgen Quality Agreement
 Ancillary Agreements
 BI Austria
 BI Austria Agreement
 BLA
 Business Day
 Code
 Confidentiality Agreement
 Contract
 Employee Liabilities
 44.




---



##### 



Encumbrance
 Excluded Amgen Materials
 Excluded Assets
 Excluded BI Materials
 Excluded Liabilities Section
5.10(b) Section
5.10(c) Section
5.10(d) Section
5.10(e)
 FDA
 Governmental or Regulatory Authority
 ***Confidential Treatment Requested
 45.




---



##### 



HSR Act
 IND
 Infergen ®
 Infergen Manufacturing Transfer Payment
 Instruments of Transfer
 Intellectual Property
 ***Confidential Treatment Requested
 46.




---



##### 



InterMune
 InterMune Agreement
 InterMune Milestone Payment
 Kenco
 Kenco Agreement
 Knowledge of Seller Sellers Knowledge
 Law
 Liability
 Material Consents Section 6.2(d)
 NDA
 ***Confidential Treatment Requested
 47.




---



##### 



NDC
 Non-Solicitation Agreement
 Other Intellectual Property Schedule 1.1(b)
 Permitted Encumbrances Section 3.6
 Person
 Product Business
 Product Copyrights Section 1.1(a)(iii)(A)
 Product Domains Section 1.1(a)(iii)(B)
 Product Know-How
 48.




---



##### 



Product Material Adverse Effect
 Product Patents Section 1.1(a)(iii)(C)
 Product Registrations
 Product Trade Dress Section 1.1(a)(iii)(D)
 Product Trademarks Section 1.1(a)(iii)(E)
 Roche/Genentech License Agreement
 ***Confidential Treatment Requested
 49.




---



##### 



Tax
 Tax Return
 Territory
 Third Party
 Trademarks
 United States
 Wholesalers
 Wholesaler Inventory Amount
 Wholesaler Inventory Rebate
 Wholesaler Target Amount
 50.




---



##### 



12-Month Anniversary Date
    
    1.5(b)12-Month Payment
    
    1.5(b)18-Month Anniversary Date
    
    1.5(c)18-Month Payment
    
    1.5(c)AAA
    
    9.3(a)Actions
    
    3.8(b)Agreement
    
    PreambleAllocation
    
    1.7Amgen Materials
    
    1.3(c)Assumed Contracts
    
    1.1(a)(iv)Assumed Liabilities
    
    1.3Basket
    
    8.5(a)Bill of Sale
    
    2.2(a)BI Materials
    
    1.3(d)Buyer
    
    PreambleBuyer Indemnitees
    
    8.2(a)Buyers Closing Certificate
    
    6.3(c)Cap
    
    8.5(a)Chargeback Claims
    
    5.10(e)(i)Closing
    
    2.1Closing Date
    
    2.1Closing Payment
    
    1.5(a)Commercial Rebate Tail Period
    
    5.10(d)(i)(1)Commercial Rebates
    
    5.10(d)(i)Competing Product
    
    5.12Dispute
    
    9.3(a)DOJ
    
    5.4(a)Effective Time
    
    2.1Electing Buyer
    
    8.4Enforceability Exceptions
    
    3.2Excluded Representations
    
    8.1Execution Date
    
    PreambleFinancing
    
    4.4Financing Letter
    
    4.4FTC
    
    5.4(a)General Assignment
    
    2.2(b)Government Rebate Tail Period
    
    5.10(c)(i)(1)Government Rebates
    
    5.10(c)(i)Indemnification Claim Notice
    
    8.3(a)Indemnified Party
    
    8.3(a)Indemnifying Party
    
    8.3(a)Inventory
    
    1.1(a)(vi)Inventory Disposal Costs
    
    1.1(a)(vi)Losses
    
    8.2(a)
 51.




---



##### 



Material Contracts
    
    3.10(a)Non-Responsible Party
    
    5.10(c)(ii)Outside Date
    
    7.1(b)Patent Assignment
    
    2.2(c)Post-Closing Period
    
    2.4(c)Pre-Closing Period
    
    2.4(b)Product
    
    RecitalsProduct Financial Statements
    
    3.15Product Intellectual Property
    
    1.1(a)(iii)Product Records
    
    1.1(a)(v)Product Regulatory Approvals
    
    1.1(a)(i)Product Returns
    
    5.10(b)(i)Promotional Materials
    
    1.1(a)(ii)Purchase Price
    
    1.5Regulatory Consents
    
    3.3(a)Responsible Party
    
    5.10(c)(ii)Returned Product
    
    5.10(b)(ii)Rules
    
    9.3(a)SAE
    
    5.14(b)Seller
    
    PreambleSeller Marks
    
    5.18Seller Disclosure Letter
    
    3.14Seller Indemnitees
    
    8.2(b)Sellers Closing Certificate
    
    6.2(e)Straddle Period
    
    2.4(d)Tax Claim
    
    2.4(g)Third Party Claim
    
    8.3(a)Trademark Assignment
    
    2.2(d)Transfer
    
    1.1(a)Transfer Taxes
    
    2.4(a)Transferred Assets
    
    1.1(a)Transferred Employee
    
    5.13Transition Related Payments
    
    2.2(k)Transition Services Agreement
    
    Recitals
 Notices
 52.




---



##### 



If to Seller:
 
 with a copy to
 
 If to Buyer:
 
 with a copy to
 
 Dispute Resolution
 Section 9.3(b) Dispute Section 9.3 Section
9.3(b) AAA Rules
  53.




---



##### 



Section 9.3(d)
  except that
 Section 9.3(a)
 et seq
 Section 9.3(a)
  54.




---



##### 



Interpretation
 Amendment
 Entire Agreement Section 5.9
 Assignment provided however provided further
 Third Parties Article VIII
 55.




---



##### 



Waiver
 Severability
 Governing Law
 Headings
 Execution in Counterparts
 Relationship of the Parties
  56.




---



##### 



THREE RIVERS PHARMACEUTICALS, LLCBy:

/s/ Donald J. KerrishTitle:
    President and CEOVALEANT PHARMACEUTICALS NORTH AMERICABy:

/s/Timothy C. TysonTitle:
    President and CEO 57.